Pulse Journal Club Active Debates Trending Explore Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia | Synapse

November 14, 2006Open Access

Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, was effective in increasing serum sodium concentrations at day 4 and day 30. (ClinicalTrials.gov numbers, NCT00072683 ClinicalTrials.gov SALT-1 and NCT00201994 ClinicalTrials.gov SALT-2.).

Read Full Paperexternally

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Schrier et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd44398557d5ab8f40c743 https://doi.org/https://doi.org/10.1056/nejmoa065181

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.1986 · 558 citations
2More powerful procedures for multiple significance testing1990 · 2,806 citations
3Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation2006 · 193 citations
4Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients.1980 · 82 citations
5Acute Aquaresis by the Nonpeptide Arginine Vasopressin (AVP) Antagonist OPC-31260 Improves Hyponatremia in Patients with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)1997 · 135 citations